Hookipa Pharma Inc.

07/29/2025 | Press release | Distributed by Public on 07/29/2025 14:02

Proxy Results (Form 8-K)

Item 5.07 Submission of Matters to a Vote of Security Holders.

On July 29, 2025, HOOKIPA Pharma Inc. (the "Company") held a special meeting of stockholders (the "Special Meeting"). As of June 17, 2025, the record date for the Special Meeting, there were 9,799,053 shares of the Company's common stock outstanding and entitled to vote at the Special Meeting. At the Special Meeting, 5,304,559 shares were present in person or represented by proxy, constituting 54.13% of the voting power on the record date. A quorum was present for all matters.

The Company's stockholders voted on the following matters, which are described in detail in the Company's definitive proxy statement (the "Proxy Statement") filed with the U.S. Securities and Exchange Commission on July 3, 2025:

(i) To approve the sale of certain assets of the Company pursuant to the Asset Purchase Agreement dated May 21, 2025 by and among the Company, Hookipa Biotech GmbH and Gilead Sciences, Inc. (the "Asset Sale Proposal");
(ii) To approve the liquidation and dissolution of the Company and the Plan of Dissolution (as defined in the Proxy Statement), which, if approved, will authorize the Company to dissolve and liquidate as described in the Plan of Dissolution (the "Dissolution Proposal"); and
(iii) To approve one or more adjournments of the Special Meeting from time to time, if necessary, to solicit additional proxies in the event that there are insufficient shares present virtually or represented by proxy voting in favor of the Asset Sale Proposal or the Dissolution Proposal (the "Adjournment Proposal").

The Company's stockholders approved the Asset Sale Proposal. The votes cast at the Special Meeting were as follows:

For Against Abstain
5,063,462 239,595 1,502

The Company's stockholders approved the Dissolution Proposal. The votes cast at the Special Meeting were as follows:

For Against Abstain
4,969,875 329,803 4,881

The Company's stockholders approved the Adjournment Proposal. The votes cast at the Special Meeting were as follows:

For Against Abstain
5,110,153 191,383 3,023
Hookipa Pharma Inc. published this content on July 29, 2025, and is solely responsible for the information contained herein. Distributed via Edgar on July 29, 2025 at 20:02 UTC. If you believe the information included in the content is inaccurate or outdated and requires editing or removal, please contact us at [email protected]